176 related articles for article (PubMed ID: 31848295)
21. Effect of costunolide and dehydrocostus lactone on cell cycle, apoptosis, and ABC transporter expression in human soft tissue sarcoma cells.
Kretschmer N; Rinner B; Stuendl N; Kaltenegger H; Wolf E; Kunert O; Boechzelt H; Leithner A; Bauer R; Lohberger B
Planta Med; 2012 Nov; 78(16):1749-56. PubMed ID: 23047249
[TBL] [Abstract][Full Text] [Related]
22. 1H-cyclopenta[b]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines.
Bohnenstengel FI; Steube KG; Meyer C; Quentmeier H; Nugroho BW; Proksch P
Z Naturforsch C J Biosci; 1999 Dec; 54(12):1075-83. PubMed ID: 10685499
[TBL] [Abstract][Full Text] [Related]
23. Structurally Modified Cyclopenta[
Agarwal G; Wilson JR; Kurina SJ; Anaya-Eugenio GD; Ninh TN; Burdette JE; Soejarto DD; Cheng X; Carcache de Blanco EJ; Rakotondraibe LH; Kinghorn AD
J Nat Prod; 2019 Oct; 82(10):2870-2877. PubMed ID: 31621322
[TBL] [Abstract][Full Text] [Related]
24. Silvestrol regulates G2/M checkpoint genes independent of p53 activity.
Mi Q; Kim S; Hwang BY; Su BN; Chai H; Arbieva ZH; Kinghorn AD; Swanson SM
Anticancer Res; 2006; 26(5A):3349-56. PubMed ID: 17094452
[TBL] [Abstract][Full Text] [Related]
25. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
[TBL] [Abstract][Full Text] [Related]
26. Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae).
Bohnenstengel FI; Steube KG; Meyer C; Nugroho BW; Hung PD; Kiet LC; Proksch P
Z Naturforsch C J Biosci; 1999; 54(1-2):55-60. PubMed ID: 10223787
[TBL] [Abstract][Full Text] [Related]
27. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.
Polier G; Neumann J; Thuaud F; Ribeiro N; Gelhaus C; Schmidt H; Giaisi M; Köhler R; Müller WW; Proksch P; Leippe M; Janssen O; Désaubry L; Krammer PH; Li-Weber M
Chem Biol; 2012 Sep; 19(9):1093-104. PubMed ID: 22999878
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Yamashita AS; Baia GS; Ho JS; Velarde E; Wong J; Gallia GL; Belzberg AJ; Kimura ET; Riggins GJ
J Neurooncol; 2014 May; 118(1):83-92. PubMed ID: 24668609
[TBL] [Abstract][Full Text] [Related]
29. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
30. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
[TBL] [Abstract][Full Text] [Related]
33. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.
Hwang BY; Su BN; Chai H; Mi Q; Kardono LB; Afriastini JJ; Riswan S; Santarsiero BD; Mesecar AD; Wild R; Fairchild CR; Vite GD; Rose WC; Farnsworth NR; Cordell GA; Pezzuto JM; Swanson SM; Kinghorn AD
J Org Chem; 2004 May; 69(10):3350-8. PubMed ID: 15132542
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
[TBL] [Abstract][Full Text] [Related]
35. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
[TBL] [Abstract][Full Text] [Related]
36. Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans from
Greger H
Phytochem Rev; 2022; 21(3):725-764. PubMed ID: 34104125
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
39. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4'-desmethoxyepisilvestrol.
Adams TE; El Sous M; Hawkins BC; Hirner S; Holloway G; Khoo ML; Owen DJ; Savage GP; Scammells PJ; Rizzacasa MA
J Am Chem Soc; 2009 Feb; 131(4):1607-16. PubMed ID: 19140688
[TBL] [Abstract][Full Text] [Related]
40. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
